by Tina Zhou  , Sara Khan  , Ron Firestein  , Peter Downie  and Jason E Cain

Received: 29 November 2018;  Published: 12 March 2019;  doi: 10.21926/obm.neurobiol.1901022

Pediatric brain tumors account for approximately 25% of all cancers in children and are currently the leading cause of cancer-related deaths in the pediatric population with an estimated incidence of 5.14 cases per 100,000 persons [1]. Up to 10-15% of all pediatric brain tumors arise in the brainste [...]

by Alberto Feletti  , Elena Bianchini  , Anna De Gaetano  , Lara Gibellini  , Sara De Biasi  , Giacomo Pavesi  , Anna Vittoria Mattioli  , Milena Nasi  , Andrea Cossarizza  and Marcello Pinti

Received: 26 November 2018;  Published: 04 March 2019;  doi: 10.21926/obm.neurobiol.1901021

Hemangioblastomas (HBs) are benign, highly vascularized tumors of the central nervous system. About 75% of HBs are sporadic, while 25% are associated with von Hippel-Lindau (VHL) disease. HBs consist of two main components, a rich capillary network composed of vascular endothelia and pericytes, with [...]

by Pilar López-Larrubia  , Nuria Arias-Ramos  and Jesús Pacheco-Torres

Received: 11 November 2018;  Published: 30 January 2019;  doi: 10.21926/obm.neurobiol.1901020

Background: Despite the advances in multimodal therapeutic options, glioblastoma (GBM), the most frequent and aggressive of all astrocytomas, remains with a median survival of 15 months. It is reported a direct correlation between GBM hypoxia and a higher aggressiveness, poor prognosis and greater r [...]

by Kirsten Greenlaw  and Jai Jai Shiva Shankar

Received: 07 October 2018;  Published: 13 January 2019;  doi: 10.21926/obm.neurobiol.1901019

Background and Purpose: Perfusion imaging, mainly MR perfusion (MRP), is performed frequently for brain tumor imaging. CT perfusion (CTP) is less studied as a method for characterizing brain tumors. The purpose of this study was to demonstrate the usefulness of CTP perfusion parameters in evaluating [...]

by Rahul Abhyankar  , Divya B. Mella  and Edward Pan

Received: 12 November 2018;  Published: 04 January 2019;  doi: 10.21926/obm.neurobiol.1901018

Objective: To report a unique case of cerebellopontine angle glioblastoma with concurrent spinal cord involvement. Background: Glioblastoma (GBM) is the most common primary malignancy of the central nervous system (CNS), comprising 46.6% of all CNS malignancies. By anatomic location, cerebelloponti [...]

by Melissa A. Maloney  , Katherine E. Lewinter  , Sally L. Davidson Ward  and Iris A. Perez

Received: 13 November 2018;  Published: 16 December 2018;  doi: 10.21926/obm.neurobiol.1804017

Sleep complaints are common in pediatric patients with central nervous system (CNS) tumors. These problems may result from disruption of normal homeostatic, circadian, neuroendocrine, and cardiorespiratory pathways and vary by tumor location and treatment received. Children with tumors within the hy [...]

by Michele Bisceglia  , Stefano Pizzolitto  , Tullio Parracino  , Giovanna De Maglio  , Elena Minenna  , Serena D’Agostini  and Carlos A. Galliani

Received: 07 October 2018;  Published: 14 November 2018;  doi: 10.21926/obm.neurobiol.1804016

Thyroid transcription factor 1 (TTF-1) is a nuclear polypeptide, tissue-restricted member of the homeobox protein family, that when attached to DNA plays a crucial role in regulating the expression of select genes during early embryonic development of the thyroid, lung, and brain. As often happens, [...]

by Richard A. Prayson

Received: 04 September 2018;  Published: 05 November 2018;  doi: 10.21926/obm.neurobiol.1804015

Along with focal cortical dysplasia, hippocampal sclerosis and remote infarcts, tumors are a well known cause of medically intractable or pharmacoresistent epilepsy [1-3]. Most of the tumors encountered in this setting represent low grade glioneuronal neoplasms, particularly gangliogliomas and dyse [...]

by Divya B. Mella  , Josie Sewell  and Edward Pan

Received: 12 October 2018;  Published: 01 November 2018;  doi: 10.21926/obm.neurobiol.1804014

Objective: To report three cases of refractory prolactinomas treated with Temozolomide (TMZ). Background: Prolactinomas account for 40% of pituitary adenomas. Dopamine agonists (DA) are the first line of treatment followed by surgical resection and radiation. TMZ is an oral chemotherapeutic agent us [...]

by Jai Jai Shiva Shankar  , Adil Bata  and Namita Sinha

Received: 07 August 2018;  Published: 25 October 2018;  doi: 10.21926/obm.neurobiol.1804013

Background: Current imaging standard for detecting and assessing glioblastoma multiforme (GBM) progression depends on contrast-enhancement on brain magnetic resonance imaging (MRI). Isolated foci of diffusion restriction have been observed to precede enhancement in GBM. The aim of our study was to i [...]